Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia vera

Long-term follow-up data from the ongoing phase III RESPONSE trial, released at the 2017 American Society of Hematology Annual Meeting, show continued safety and response of ruxolitinib in patients with polycythemia vera resistant or intolerant to hydroxyurea.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.